FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

被引：472

作者：

Fischer, Christian ^{[2
]}

Mazzone, Massimiliano ^{[1
,3
]}

Jonckx, Bart ^{[1
,3
]}

Carmeliet, Peter ^{[1
,3
]}

机构：

[1] VIB, Flanders Inst Biotechnol, Vesalius Res Ctr, B-3000 Louvain, Belgium

[2] Charite, Dept Gastroenterol & Hepatol, D-13353 Berlin, Germany

[3] Katholieke Univ Leuven, Vesalius Res Ctr, B-3000 Louvain, Belgium

来源：

NATURE REVIEWS CANCER | 2008年 / 8卷 / 12期

关键词：

D O I：

10.1038/nrc2524

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Less than 5 years ago, it was still not clear whether anti-angiogenic drugs would prove successful in the clinic. After numerous patients with cancer or age-related macular degeneration have been treated with these drugs, they have now become part of the standard range of therapeutic tools. Despite this milestone, anti-angiogenic therapy still faces a number of clinical hurdles, such as improving efficacy, avoiding escape and resistance, and minimizing toxicity. Hopefully, other agents with complementary mechanisms, such as those that target placental growth factor, will offer novel opportunities for improved treatment.

引用

页码：942 / 956

页数：15

共 210 条

[1] Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect [J].

Aase, K ;

von Euler, G ;

Li, X ;

Pontén, A ;

Thorén, P ;

Cao, R ;

Cao, Y ;

Olofsson, B ;

Gebre-Medhin, S ;

Pekny, M ;

Alitalo, K ;

Betsholtz, C ;

Eriksson, U .

CIRCULATION, 2001, 104 (03) :358-364

[2] Selective downregulation of VEGF-A165, VEGF-R1, and decreased capillary density in patients with dilative but not ischemic cardiomyopathy [J].

Abraham, D ;

Hofbauer, R ;

Schäfer, R ;

Blumer, R ;

Paulus, P ;

Miksovsky, A ;

Traxler, H ;

Kocher, A ;

Aharinejad, S .

CIRCULATION RESEARCH, 2000, 87 (08) :644-647

[3]

Adini A, 2002, CANCER RES, V62, P2749

[4] Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis [J].

Afuwape, AO ;

Feldmann, M ;

Paleolog, EM .

GENE THERAPY, 2003, 10 (23) :1950-1960

[5]

André T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO

[6]

2-5

[7] Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 [J].

Autiero, M ;

Waltenberger, J ;

Communi, D ;

Kranz, A ;

Moons, L ;

Lambrechts, D ;

Kroll, J ;

Plaisance, S ;

De Mol, M ;

Bono, F ;

Kliche, S ;

Fellbrich, G ;

Ballmer-Hofer, K ;

Maglione, D ;

Mayr-Beyrle, U ;

Dewerchin, M ;

Dombrowski, S ;

Stanimirovic, D ;

Van Hummelen, P ;

Dehio, C ;

Hicklin, DJ ;

Persico, G ;

Herbert, JM ;

Communi, D ;

Shibuya, M ;

Collen, D ;

Conway, EM ;

Carmeliet, P .

NATURE MEDICINE, 2003, 9 (07) :936-943

[8] Coordinated activation of VEGFR-1 and VEGFR-2 is a potent arteriogenic stimulus leading to enhancement of regional perfusion [J].

Babiak, A ;

Schumm, AM ;

Wangler, C ;

Loukas, M ;

Wu, JB ;

Dombrowski, S ;

Matuschek, C ;

Kotzerke, J ;

Dehio, C ;

Waltenberger, J .

CARDIOVASCULAR RESEARCH, 2004, 61 (04) :789-795

[9] Anti-Flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis [J].

Bae, DG ;

Kim, TD ;

Li, G ;

Yoon, WH ;

Chae, CB .

CLINICAL CANCER RESEARCH, 2005, 11 (07) :2651-2661

[10] Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling [J].

Baffert, F ;

Le, T ;

Sennino, B ;

Thurston, G ;

Kuo, CJ ;

Hu-Lowe, D ;

McDonald, DM .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 290 (02) :H547-H559

← 1 2 3 4 5 6 7 8 9 10 →